{"filings":[{"id":93839,"accession_number":"0001581280-26-000037","cik":1581280,"company_name":"Twist Bioscience Corp","ticker":"TWST","form_type":"8-K","filed_at":"2026-05-04T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Twist Bioscience Q2 revenue $110.7M (+19% YoY); raises FY2026 revenue guidance to $442-447M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Record revenue $110.7M, 13th consecutive quarter of sequential growth; gross margin 51.6% (+2 pts YoY).","DSPS revenue $53.3M (+28% YoY); NGS revenue $57.4M (+12% YoY).","Net loss $44M ($0.71/share) vs $39.3M ($0.66/share) YoY; adjusted EBITDA loss improved to $13.3M from $14.8M.","Raised FY2026 revenue guidance to $442-447M; reiterates Q4 FY26 adjusted EBITDA breakeven.","Booked $7.2M litigation settlement cost for securities class action; entered bispecific licensing with Invenra."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.21,"consensus_revenue_estimate":null,"consensus_revenue_actual":214413000.0,"consensus_period":"2026-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":4295475028.619916,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":105772,"accession_number":"0001104659-26-015730","cik":1581280,"company_name":"Twist Bioscience Corp","ticker":"TWST","form_type":"8-K","filed_at":"2026-02-17T23:59:59+00:00","items":["3.02","8.01","9.01"],"status":"ready","headline":"Twist Bioscience to issue up to 632,328 shares for Invenra license and equity stake","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Total consideration: up to 632,328 TWST shares plus $5M cash.","324,558 shares + $5M to Invenra for license and technology transfer.","307,770 shares to two Invenra investors for ~6% preferred stock ownership.","Twist gains right to designate one director to Invenra board.","Registration Rights Agreements filed to register resale of issued shares."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":4295475028.619916,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":105771,"accession_number":"0001581280-26-000022","cik":1581280,"company_name":"Twist Bioscience Corp","ticker":"TWST","form_type":"8-K","filed_at":"2026-02-06T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Twist Bioscience stockholders elect three directors, approve say-on-pay and auditor ratification at 2026 annual meeting","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Keith Crandell, Jan Johannessen, and Trynka Shineman Blake elected as Class II directors with over 40M votes for each.","Non-binding advisory vote to approve NEO compensation passed: 38.4M for, 11.8M against, 32.7K abstentions.","Ratification of Ernst & Young as auditor for FY2026 approved: 56.2M for, 18.2K against, 21.8K abstentions."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":4295475028.619916,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":105770,"accession_number":"0001581280-26-000016","cik":1581280,"company_name":"Twist Bioscience Corp","ticker":"TWST","form_type":"8-K","filed_at":"2026-02-02T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Twist Bioscience Q1 FY26: Record revenue $103.7M (+17% YoY), raises FY guidance to $435-440M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $103.7M (+17% YoY), 12th consecutive sequential growth; exceeded guidance.","Gross margin 52.0% (+4 pts YoY); net loss narrowed to $30.5M ($0.50/share) vs $31.6M.","DNA Synthesis & Protein Solutions rev $51.1M (+27% YoY); NGS Apps $52.6M (+8%, ex-large customer +18%).","FY2026 revenue guidance raised to $435-440M; reaffirms Q4 Adj EBITDA breakeven on track.","Cash $198M; shipped to ~2,538 customers, ~271,000 genes; launched research-grade plasmid DNA preps."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.5,"consensus_revenue_estimate":null,"consensus_revenue_actual":103698000.0,"consensus_period":"2026-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":4295475028.619916,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":105769,"accession_number":"0001581280-26-000012","cik":1581280,"company_name":"Twist Bioscience Corp","ticker":"TWST","form_type":"8-K","filed_at":"2026-01-12T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Twist Bioscience preliminary Q1 FY2026 revenue ~$103.7M, up 17% YoY, ahead of guidance","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Preliminary Q1 FY2026 revenue ~$103.7M (+/- $0.2M), 17% YoY growth, above guidance of $100-101M.","DNA Synthesis & Protein Solutions revenue $51.1M (+/- $0.1M), up 27% YoY.","NGS Applications revenue $52.6M (+/- $0.1M), ahead of guidance; excluding one customer transition, NGS grew 18% YoY.","Full Q1 financial results to be reported on Feb 2, 2026, before market open."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.5,"consensus_revenue_estimate":null,"consensus_revenue_actual":103698000.0,"consensus_period":"2026-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":4295475028.619916,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":122057,"accession_number":"0001581280-25-000020","cik":1581280,"company_name":"Twist Bioscience Corp","ticker":"TWST","form_type":"8-K","filed_at":"2025-11-14T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Twist Bioscience FY2025 revenue $376.6M (+20% YoY); guides for adjusted EBITDA breakeven in Q4 FY2026","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Record FY2025 revenue $376.6M (+20% YoY); Q4 revenue $99.0M (+17% YoY), 11th consecutive sequential growth.","FY25 gross margin 50.7% vs 42.6% in FY24; Q4 gross margin 51.3% vs 45.1%.","NGS segment revenue grew 23% to $208.1M; SynBio grew 17% to $145.0M; Biopharma grew 15% to $23.5M.","Net loss narrowed to $77.7M ($1.30/share) from $208.7M ($3.60/share); adjusted EBITDA -$46.9M vs -$93.5M.","FY2026 guidance: maintain gross margin >50%; target adjusted EBITDA breakeven by Q4 FY2026."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.3,"consensus_revenue_estimate":null,"consensus_revenue_actual":376572000.0,"consensus_period":"2025-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":4295475028.619916,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":138768,"accession_number":"0001581280-25-000012","cik":1581280,"company_name":"Twist Bioscience Corp","ticker":"TWST","form_type":"8-K","filed_at":"2025-08-06T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Twist Bioscience appoints Trynka Shineman Blake to Board of Directors","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Trynka Shineman Blake elected to Twist board and appointed to Audit Committee, effective August 5, 2025.","Blake most recently served as CEO of Vistaprint; brings ~30 years in digital transformation, customer experience, and global marketing.","Compensation includes $50k annual cash retainer, $10k audit retainer, initial RSU of $395k fair value, and annual RSU of $240k.","Blake also serves on boards of Tripadvisor, Semrush, Captura, and Steer.","CEO Emily Leproust cites Blake's proven track record in scaling profitable growth and customer-centric culture."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":4295475028.619916,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":138767,"accession_number":"0001581280-25-000006","cik":1581280,"company_name":"Twist Bioscience Corp","ticker":"TWST","form_type":"8-K","filed_at":"2025-08-04T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Twist Bioscience reports record Q3 revenue $96.1M (+18% YoY); swings to GAAP net income $20.4M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Record revenue $96.1M, up 18% YoY; NGS revenue grew 27% to $55.3M.","Gross margin improved to 53.4% from 43.3% YoY; net income $20.4M ($0.34/share) vs loss $85.6M.","FY2025 revenue guidance raised to $374-376M; gross margin guidance raised to 50.5%-51%.","Adjusted EBITDA loss narrowed to $(8.0)M from $(22.0)M; expect breakeven by end of FY2026.","Added ~184 net new customers; shipped 237,000 genes, up 12% YoY."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.85,"consensus_revenue_estimate":null,"consensus_revenue_actual":277563000.0,"consensus_period":"2025-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":4295475028.619916,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":156218,"accession_number":"0001104659-25-044352","cik":1581280,"company_name":"Twist Bioscience Corp","ticker":"TWST","form_type":"8-K","filed_at":"2025-05-05T23:59:59+00:00","items":["1.01","2.02","7.01","9.01"],"status":"ready","headline":"Twist reports record Q2 revenue $92.8M; spins out DNA data storage as Atlas with $155M investment","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Record Q2 revenue $92.8M (+23% YoY); gross margin 49.6% vs 41.0%.","Net loss $39.3M ($0.66/sh) vs $45.5M ($0.79); adjusted EBITDA loss improved to $(14.8)M.","Spun out DNA data storage as Atlas Data Storage with $155M investment from ARCH, Deerfield, Bezos Expeditions, and others.","Atlas CEO Varun Mehta (ex-Nimble Storage) leads; Twist retains minority stake, $2.5M cash, $2M note, up to $75M milestones.","Guidance: FY2025 revenue $372-379M; expect gross margin >50% in Q4; adjusted EBITDA breakeven by end of FY2026."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.9,"calibrated_materiality_score":0.9,"market_cap_usd":4295475028.619916,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":174672,"accession_number":"0001104659-25-011543","cik":1581280,"company_name":"Twist Bioscience Corp","ticker":"TWST","form_type":"8-K","filed_at":"2025-02-11T23:59:59+00:00","items":["5.02","5.07","5.03","9.01"],"status":"ready","headline":"Twist Bioscience shareholders approve 100M share increase, equity plan amendment","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Shareholders approved increase in authorized common stock by 100,000,000 shares (Proposal Five).","Amendment and restatement of 2018 Equity Incentive Plan approved; 3,700,000 new shares reserved (Proposal Four).","Directors Nelson Chan, Robert Ragusa, Melissa Starovasnik re-elected as Class I directors.","Non-binding advisory vote on NEO compensation passed with 49.6M votes for; 1.2M against.","Officer exculpation amendment approved (46.5M for, 4.3M against) effective upon filing Certificate of Amendment."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":4295475028.619916,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":174671,"accession_number":"0001628280-25-003387","cik":1581280,"company_name":"Twist Bioscience Corp","ticker":"TWST","form_type":"8-K","filed_at":"2025-02-03T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Twist Bioscience Q1 FY2025 revenue $88.7M (+24% YoY), gross margin 48.3%, net loss narrows to $31.6M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Total revenue $88.7M vs $71.5M YoY; SynBio +28% to $34.4M, NGS +23% to $48.6M.","Gross margin improved 7.8 points to 48.3% from 40.5% in prior year period.","Net loss per share ($0.53) vs ($0.75) YoY; adjusted EBITDA ($16.3M) vs ($27.8M).","FY2025 revenue guidance $372M-$379M; expects gross margin over 50% in Q4 FY2025.","Cash and short-term investments $270.8M at Dec 31, 2024; shipped to ~2,376 customers."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.53,"consensus_revenue_estimate":null,"consensus_revenue_actual":88713000.0,"consensus_period":"2025-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":4295475028.619916,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":191639,"accession_number":"0001628280-24-048173","cik":1581280,"company_name":"Twist Bioscience Corp","ticker":"TWST","form_type":"8-K","filed_at":"2024-11-18T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Twist Bioscience FY2024 rev $313.0M (+28% YoY); Q4 gross margin 45.1%; FY2025 rev guidance $367M-$377M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["FY2024 revenue $313.0M, up 28% vs FY2023; Q4FY24 revenue $84.7M, up 27% YoY, 7th consecutive sequential growth.","Gross margin improved to 45.1% in Q4FY24 (from 36.6%); net loss narrowed to $34.7M ($0.59/share) from $46.2M ($0.81/share).","FY2025 guidance: revenue $367M-$377M; targeting 50% gross margin by Q4FY25.","Adjusted EBITDA improved to -$93.5M FY2024 vs -$147.3M FY2023; cash $276.4M at year-end.","Entered $15M royalty purchase agreement with XOMA; launched FlexPrep NGS kit with proprietary enzyme."],"consensus_eps_estimate":null,"consensus_eps_actual":-3.6,"consensus_revenue_estimate":null,"consensus_revenue_actual":312974000.0,"consensus_period":"2024-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":4295475028.619916,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":191638,"accession_number":"0001104659-24-108591","cik":1581280,"company_name":"Twist Bioscience Corp","ticker":"TWST","form_type":"8-K","filed_at":"2024-10-15T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Twist Bioscience enters month-to-month consulting agreement with James Thorburn at $25K/mo","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["James Thorburn's previous employment agreement as Strategic Advisor expired; new consulting deal effective October 8, 2024.","Consulting agreement is month-to-month at $25,000 per month to complete certain projects.","No departure of director or officer; Thorburn continues in a limited advisory capacity."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":4295475028.619916,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":208105,"accession_number":"0001628280-24-034277","cik":1581280,"company_name":"Twist Bioscience Corp","ticker":"TWST","form_type":"8-K","filed_at":"2024-08-02T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Twist Bioscience Q3 FY2024 revenue $81.5M (+28% YoY); raises FY2024 guidance to ~$310-311M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $81.5M, up 28% YoY; gross margin 43.3%, up ~900 bps from 34.4%.","Net loss GAAP $85.6M ($1.47/sh) includes $45M Biopharma impairment; adjusted net loss $40.6M.","Adjusted EBITDA improved to $(22.0)M from $(29.6)M YoY; orders grew to $85.3M.","FY2024 revenue guidance raised to ~$310-311M; gross margin guidance ~42% (high end).","SynBio revenue $33.0M, NGS $43.4M, Biopharma $5.1M; cash $289.4M."],"consensus_eps_estimate":null,"consensus_eps_actual":-3.01,"consensus_revenue_estimate":null,"consensus_revenue_actual":228264000.0,"consensus_period":"2024-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":4295475028.619916,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":225654,"accession_number":"0001628280-24-019999","cik":1581280,"company_name":"Twist Bioscience Corp","ticker":"TWST","form_type":"8-K","filed_at":"2024-05-02T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Twist Bioscience reports record Q2 revenue $75.3M (+25% YoY), raises FY2024 guidance","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Record revenue $75.3M (+25% YoY); orders $93.2M (+45% YoY).","Net loss $45.5M ($0.79/sh) vs $59.2M ($1.04) YoY; adjusted EBITDA -$26.8M.","Gross margin improved to 41% from 31%; FY2024 revenue guidance raised to $300-304M, gross margin 41.5-42.0%.","Cash burn improved: net cash from ops -$42.4M H1FY24 vs -$98.4M; cash $293.3M.","NGS revenue $40.8M (+41% YoY), SynBio $29.8M (+23%), Biopharma $4.7M (-33%)."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.54,"consensus_revenue_estimate":null,"consensus_revenue_actual":146800000.0,"consensus_period":"2024-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":4295475028.619916,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":null}